Table 1.
6-Keto-PGF1α and TXB2 production as well as the ratio of 6-keto-PGF1α to TXB2 production in vehicle- and GA-treated PRAs under basal and ACh-stimulated conditions for piglets exposed to control and hypoxic conditions for 3 and 10 days
| 3-Day Control | 3-Day Hypoxia | 10-Day Control | 10-Day Hypoxia | |
|---|---|---|---|---|
| 6-keto-PGF1α production, pg/ml | ||||
| Vehicle-treated PRAs | ||||
| Basal | 7,286 ± 771 | 2,918 ± 303 | 6,283 ± 1,177 | 2,946 ± 403 |
| ACh stimulation | 8,793 ± 947* | 3,394 ± 294* | 12,697 + 2,641 | 3,908 ± 556* |
| GA-treated PRAs | ||||
| Basal | 9,177 ± 1,315 | 3,381 ± 287 | 8,449 ± 1,369 | 4,404 ± 601 |
| ACh stimulation | 9,528 ± 1,815 | 3,246 ± 267 | 9,224 ± 1,685 | 3,908 ± 457 |
| TXB2 production, pg/mg | ||||
| Vehicle-treated PRAs | ||||
| Basal | 3.3 ± 0.9 | 5.0 ± 0.4 | 2.5 ± 0.7 | 1.9 ± 0.6 |
| ACh stimulation | 6.0 ± 1.9* | 6.2 ± 0.5 | 2.3 ± 0.6 | 2.9 ± 0.7* |
| GA-treated PRAs | ||||
| Basal | 5.0 ± 1.0 | 5.2 ± 0.5 | 2.0 ± 0.5 | 2.6 ± 0.8 |
| ACh stimulation | 4.0 ± 1.0 | 4.8 ± 1.4 | 2.0 ± 0.5 | 3.2 ± 0.7 |
| Ratio of 6-keto-PGFαto TXB2production | ||||
| Vehicle-treated PRAs | ||||
| Basal | 3,307:1 ± 841:1 | 625:1 ± 60:1 | 4,772:1 ± 1,634:1 | 2,596:1 ± 706:1 |
| ACh stimulation | 2,293:1 ± 422:1* | 547:1 ± 43:1 | 7,149:1 ± 1,269:1* | 2,442:1 ± 347:1 |
| GA-treated PRAs | ||||
| Basal | 3,318:1 ± 940:1 | 750:1 ± 107:1 | 5,502:1 ± 973:1 | 2,496:1 ± 583;1 |
| ACh stimulation | 5,127:1 ± 1,242:1 | 1,322:1 ± 352:1* | 6,488:1 ± 1,613:1 | 1,910:1 ± 535:1 |
Values are means ± SD; n = 8 pulmonary resistance arteries (PRAs)/group. TXB2, thromboxane B2; GA, geldanamycin.
*
Significantly different from vehicle-treated or GA-treated PRAs under basal conditions (P < 0.05 by paired t-test).